Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Btg Plc LSE:BTG London Ordinary Share GB0001001592 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +1.00p +0.12% 834.50p 834.50p 835.00p 835.00p 834.00p 835.00p 601,495 10:49:15
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 620.5 -70.6 3.9 214.0 -

Btg Share Discussion Threads

Showing 5001 to 5023 of 6175 messages
Chat Pages: Latest  211  210  209  208  207  206  205  204  203  202  201  200  Older
DateSubjectAuthorDiscuss
14/11/2017
09:17
It looks as if The codes don't fully cover treatment costs. We will find out more soon.
cockneytrader
14/11/2017
09:13
Well i do undestand cost of sales and that when you are pushing a product it can cost lots of money but thats when you are pushing for market share. The pull side is less ecpensive when demand from the market for a product that works and is getting good feedback lessins the need for spending on promoting the product. All just my view but was not surprised that we have encountered insurance problems with V. But the insurance code will help matters.
king1pin2
14/11/2017
09:03
With respect, but I am not sure you understand cost of sales. Revenue is all well and good, but it's profit that counts!
cockneytrader
14/11/2017
08:50
Cant see that being honest cos all of the cost of bringing it to market has now been spent so even IF its not a blockbuster as first thought it will still bring in revenuue for the company.
king1pin2
14/11/2017
08:32
FD replacement had to be an appointment from inside to save embarrassment.
semper vigilans
14/11/2017
08:28
But, I hope to be proved wrong.
cockneytrader
14/11/2017
08:27
Because writing it off would save a small fortune going forward.
cockneytrader
14/11/2017
08:15
I dont have any idea why you think Varithena would be written off, The treatment works well and now that the codes are sorted should start to gain momentum. The share price has gained because all the bad news was in the share price before todays news. I think the results are solid so am happy to be in around this level. I know two that have had the treatment and both are very happy with the resuls.
king1pin2
14/11/2017
08:01
So, it looks like the Wellstat debacle was Rolf's fault? Bad timing for him to go if that is not the case. The CEO will effectively be on her own at the Q&A, I hope the analysts don't give her too easy a time of it. I am still in shock over Wellstat, it was a cataclysmic error by someone at BTG.
spyder
14/11/2017
07:56
I wonder to what extent Rolf is carrying the can for his executive responsibilities for:1 His management of currency hedging2 Due diligence in relation to the the trading manipulation of the beads business prior to the takeover of Biocompatibles 3 The decision to put cost saving over contractual liabilities for Wellstat.Each of these were significant on its own, but together have cost over $100 million in cash and impairment.
fhmktg
14/11/2017
07:37
The highest profile product with management focus is the second worst performer in revenue. What a management team we have. The repeated use of the word small sales team in the update is stunning . Do us a favour and sell out.
bargainbob
14/11/2017
07:23
Take over would yield perhaps £7 at this stage, £8 if you were lucky.
cockneytrader
14/11/2017
07:21
Good move Louise. Said his heart wasn't in it all along.
cockneytrader
14/11/2017
07:20
Vulnerable to takeover?
semper vigilans
14/11/2017
07:18
And I love the way they place Varithena under 'early' IM - the product has been available for three years. They must think we all come down with the last shower. £6 soonand perhaps £5 later.
cockneytrader
14/11/2017
07:15
How do people see here the two RNSes, without any biasness?
ashehzi
14/11/2017
07:14
As predicted. Varithena has been awful. And to lose Vistoguard was criminal. Heads must roll.
cockneytrader
13/11/2017
22:03
Bill Hunt I had a feeling in my water. Seriously that was the worse RNS ever last Monday from Louise. Should have been good news , but we need to wait a year to see. Seriously she needs to resign.
bargainbob
13/11/2017
20:11
All in all the revenue numbers for the half will be strong. However, expect a lacklustre performance from Varithena. A £55m provision ref WellStat, and last revenue stream from both Lemtrada and Vistogard. £6 here we come.
cockneytrader
13/11/2017
19:57
Not much room for error, then?
bill hunt
13/11/2017
19:30
Range tomorrow £7.20 to £6.00
bargainbob
13/11/2017
17:28
lets see what happens tomorrow. Some big buy before EoD and before results.
ashehzi
13/11/2017
14:36
@ "fhmktg13 Nov '17 - 13:40 - 4943 of 4943", price went down twice in couple of months because of court issue. I hope they won't mention even a single line about it in RNS tomorrow. Mentioning it time and again won't be beneficial. People start selling without knowing it was accounted for (rather twice).
ashehzi
Chat Pages: Latest  211  210  209  208  207  206  205  204  203  202  201  200  Older
Your Recent History
LSE
BTG
Btg
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190627 10:41:47